Ground Truth
← All peptides

Melanotan I (afamelanotide)

Melanotan-1, MT-I, MT-1, CUV1647, Nle4-D-Phe7-α-MSH, Scenesse, EI-_05x (Epitan)

The Ground Truth Score

four plain questions, never one number

FDA-approved for a rare disease; thin evidence for the tanning use people actually want it for.

Bottom line

The genuine rare high-evidence peptide, two phase III RCTs and FDA approval for erythropoietic protoporphyria, but that grade does NOT transfer to the cosmetic tanning use, where evidence is only small open-label pilots and the product is a gray-market injectable.

Does the science back it?

AProven in humans

Do real people feel it?

Mixed

Is it safe?

BCharacterized

Could it be placebo?

Probably real

Can you legally get it?

FDA-approvedPrescription medicine

An approved drug with a label, a manufacturer, and a prescribing route. This is the only tier where what is in the vial is guaranteed by anyone. Check the indication, though: approval is always for something specific, and it is rarely the use this compound is popular for.

Afamelanotide is FDA-approved (Oct 8 2019) as SCENESSE, a 16 mg subcutaneous IMPLANT for erythropoietic protoporphyria, and EMA-approved since 2014. Hold both halves of that: the approval is real and rests on phase III RCTs, and it is for a rare photosensitivity disorder via an implant placed by a clinician. The injectable vials sold for tanning are not SCENESSE, and the tanning use is not what was approved. Also approved for adult EPP in Canada, Israel and Australia. The US label gained a hypersensitivity and anaphylaxis warning in August 2024. It is not approved for vitiligo anywhere; the company expects topline phase III (CUV105) data in December 2026.

Legal status as of 2026-10-12. This is a separate axis from the grades above, and it does not move them. A vote about who may legally prepare a compound is not evidence that the compound works.

"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.

Why is the evidence this thin? It's mostly economics →

Dose at a glance

full dosing ↓

APPROVED (not a recommendation to self-use): one SCENESSE implant containing 16 mg afamelanotide, inserted subcutaneously above the anterior supra-iliac crest by a trained provider every 2 months.

Reported, not prescribed. Verify your vial and your math.

First documented human use

First controlled human use 1991 (Levine et al., JAMA. SC α-MSH analogue induced measurable tanning in volunteers); a small pharmacokinetic study in 3 men in 1997 (Ugwu, Blanchard, Dorr). This is one of the few peptides where the question is genuinely settled: pivotal phase III RCTs were completed and the drug is FDA-approved (Oct 8, 2019, for EPP).

Photoprotection (EPP)Sunless tanning (off-label)Repigmentation (vitiligo, investigational)
The deep dive

The pitch

What people claim it does

Stated plainly and neutrally, exactly as you'll hear it. We grade each one below.

  • Increases eumelanin (the photoprotective pigment) in skin without UV exposure by agonizing the MC1 receptor
  • Lets EPP patients tolerate far more pain-free light, restoring quality of life in a disease with no prior effective treatment
  • A 'natural-looking,' gradual tan with none of the sexual side effects of its cousin Melanotan II
  • Backed by real FDA approval and an EMA approval, not vaporware peptide marketing

The data behind each bullet

What actually backs it

A

FDA-approved (Oct 8, 2019) as the SCENESSE 16 mg subcutaneous implant to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).

FDA approval based on two randomized, double-blind, placebo-controlled phase III trials. EMA-approved since 2014. Orphan/rare-disease indication.

FDA Drugs@FDA. SCENESSE (afamelanotide) NDA 210797 ↗
A

In the U.S. phase III RCT, median pain-free direct-sunlight exposure was 69.4 h with afamelanotide vs 40.8 h placebo (P=0.04); the EU trial showed 6.0 h vs 0.8 h (P=0.005) over the study period.

Two multicenter double-blind placebo-controlled RCTs, n=168 total (86 drug / 81 placebo), published NEJM 2015;373:48-59. Quality-of-life and phototoxic-reaction secondary endpoints also favored drug.

PubMed. Langendonk et al., NEJM 2015, Afamelanotide for EPP ↗
C

Off-label/cosmetic tanning: it does produce melanin-independent tanning in healthy volunteers, but the human tanning evidence is only small open-label dose-ranging pilots (single-digit subject counts), not controlled efficacy or safety trials.

Original small open-label studies (Levine JAMA 1991; Ugwu, Blanchard and Dorr 1997 PK in 3 men). No randomized controlled trial has ever tested or approved afamelanotide for cosmetic tanning; gray-market injectable MT-I is unregulated and often mislabeled vs Melanotan II.

PubMed. Ugwu et al. 1997, Skin pigmentation and pharmacokinetics of melanotan-I in humans (3 men) ↗
C

Investigational for vitiligo (with NB-UVB) and previously trialed for polymorphous light eruption. The vitiligo phase III (CUV105, about 210 patients) has finished enrolling and the company expects topline results in December 2026; a pivotal phase III (CUV107) is planned to start in November 2026.

Active and prior company-sponsored phase III programs; vitiligo data not yet reported (company guidance: December 2026), PLE program did not yield approval. Promising but unproven for these uses.

ClinicalTrials.gov NCT06109649, CUV105 vitiligo Phase 3 ↗
A

SCENESSE carries a US warning for serious hypersensitivity reactions, including anaphylaxis, reported after approval.

Stated in the current FDA-approved label (added by a labeling supplement approved August 12, 2024). Label fact, not an efficacy claim.

DailyMed. SCENESSE label ↗
C

Sexual side effects (spontaneous erections, libido changes) belong to Melanotan II, not Melanotan I, a key confound, since gray-market vendors and forums routinely mix up or mislabel the two.

MT-II is the cyclic non-selective melanocortin agonist responsible for the famous self-injection erection anecdote and PT-141/bremelanotide lineage; MT-I (linear, MC1R-predominant) is not associated with sexual effects per clinical reports.

PubMed search, melanotan adverse effects review ↗

Prove it

Can you tell if it's working?

The honest test: if it's working, is there any objective way to see it, a blood marker, a scan, a wearable? For a lot of peptides the answer is no, and that's worth knowing before you spend on labs or gear.

Trackable

Skin melanin index by reflectance colorimetry, read at a UV-shielded site, is the direct objective proof it works, darkening at a covered site can only come from the drug.

Bloodwork

No blood proxy

Nothing on a routine panel confirms this one. Anyone who says otherwise is guessing.

Melanotan-1 (afamelanotide) is an alpha-MSH analog and MC1R agonist that drives eumelanin synthesis in skin melanocytes; its therapeutic action is local cutaneous pigmentation/photoprotection, which produces no measurable circulating analyte. In the pivotal EPP randomized trials it did not lower the disease's own biomarker (erythrocyte/plasma protoporphyrin) or alter liver biochemistries, so no routine bloodwork can confirm it is working.

Read this before you spend on labs

Bloodwork cannot verify melanotan-1. Its effect is cutaneous, increased eumelanin (tanning) and, in erythropoietic protoporphyria, longer pain-free sunlight exposure. Response is judged visually / by skin-reflectance and by light-tolerance and phototoxicity symptoms, not by any serum test. No routine LabCorp/Quest analyte reflects melanin synthesis, and in the randomized EPP trials afamelanotide did not lower erythrocyte protoporphyrin, plasma protoporphyrin, or alter liver biochemistries versus baseline, so even the disease's own biomarker does not track efficacy. Track it on the skin and by symptoms, not in a tube.

Other ways to track it

OtherDirect readout

Skin reflectance colorimetry / melanin index (dermatology-grade Mexameter or DSM-II ColorMeter at a clinic; standardized fixed-lighting before/after photos of a sun-shielded site as a lower-fidelity home proxy)

A working result shows a measurable rise in melanin index (a darker reflectance reading) at a fixed, UV-shielded body site such as the inner upper arm or buttock, with no sun exposure. Because the site is covered, any darkening can only come from the drug, not tanning. This is the actual therapeutic effect, not a proxy for it.

Melanotan-1 (afamelanotide) is an MC1R agonist that drives UV-independent eumelanin synthesis in melanocytes. Increased cutaneous melanin is precisely the effect the drug produces, and reflectance melanin density is the same class of readout used to quantify afamelanotide's effect in human trials, so a colorimeter measures efficacy directly.

Baseline reading at marked anatomical sites before the first dose; retest at ~2 weeks and again at ~4-6 weeks (reported window for peak pigmentation), then periodically to watch for fade.

Bottom line

The effect is purely cutaneous, and that is exactly why it is trackable: skin melanin index by reflectance colorimetry at a sun-shielded site is a genuine DIRECT objective efficacy readout (the Ground Truth page confirms there is no blood proxy). Nothing in urine, stool, sleep/wearable, CGM, VO2max, or DEXA applies, melanotan-1 does not move metabolic, body-composition, or recovery markers. MC1R genotype was dropped: it is a real and mechanistically sound responder predictor, but it is static and cannot confirm that any given course actually worked, so it is not a tracking channel. If you cannot measure pigmentation at a covered site, you have no objective confirmation.

Logging baseline vs retest is the whole game. The Truth Tracker is our free log for bloodwork, DEXA, genetics, and wearable data, bring your own numbers.

How to track it →

Mechanism

How it's assumed to work

Synthetic linear analogue of α-melanocyte-stimulating hormone (α-MSH); agonizes the melanocortin-1 receptor (MC1R) on melanocytes, driving eumelanin synthesis independently of UV, plus antioxidant, DNA-repair-enhancing, and anti-inflammatory effects. Substitutions (Nle4, D-Phe7) make it ~resistant to enzymatic degradation, giving a far longer half-life than native α-MSH. Mechanism is established (approved drug), not assumed.

Dosing & handling

What users and clinicians report

Reported, not prescribed

APPROVED (not a recommendation to self-use): one SCENESSE implant containing 16 mg afamelanotide, inserted subcutaneously above the anterior supra-iliac crest by a trained provider every 2 months. Gray-market off-label users report reconstituted SC injections in the ~0.5-1 mg/day range during a 'loading' phase then less frequent maintenance, but this is unverified, unregulated, and outside any controlled trial. Original human dose-ranging used ~0.16 mg/kg/day SC.

Doses are REPORTED, not prescribed. Only the 16 mg bimonthly implant is studied and approved, and only for EPP under medical supervision. Injectable 'Melanotan 1' from peptide vendors has no established dose, no purity guarantee, and is frequently mislabeled, never assume vial contents match the label. Confirm any product identity before use.

Timing & food

Approved implant is dosed every 2 months independent of food (it is not oral; afamelanotide has zero oral bioavailability). For the implant, timing is driven by the start of high-light-exposure seasons in EPP. Gray-market injectors often dose in the evening to sleep through nausea/flushing, but there is no food-timing rationale because it is parenteral and the effect is cumulative pigment build-up, not acute.

Half-life

Apparent half-life ~15 hours from the controlled-release SC implant; median Tmax ~36 h, mean Cmax ~3.7 ng/mL. Drug is generally undetectable in plasma within ~2-3 days of implant placement, while the pigmentation effect persists for weeks (hence the 2-month dosing interval). Native α-MSH, by contrast, degrades within minutes.

Reconstitution sensitivity

The approved product is a solid bioresorbable implant (no reconstitution). For gray-market lyophilized injectable powder, peptide-handling norms apply: reconstitute gently with bacteriostatic water, do not shake, refrigerate after mixing, protect from light and heat. Reconstitution quality is unverifiable for unregulated product, which is itself a core risk.

Real-world signal

What people actually report

Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.

Mixed signal· Reports exist but contradict each other.

Volume

Moderate-to-high chatter, but skewed: most online volume is about Melanotan II (the stronger tanning + libido peptide) and PT-141, with MT-I discussed comparatively less and frequently confused with MT-II. EPP-patient communities (e.g., porphyria foundations) discuss the approved drug seriously and separately from the tanning crowd.

Consistency

Mixed/inconsistent. EPP patient and clinical sources are consistent and positive about real benefit. The tanning-forum signal is muddier: users agree MT-I tans more slowly and 'cleaner' than MT-II (fewer side effects) but many find it underwhelming versus MT-II and pivot to the stronger compound, so the cosmetic signal partly self-selects toward its sibling.

Source credibility

Two-tier. High-credibility: peer-reviewed trials, FDA/EMA, and disease-foundation sources for the EPP indication. Low-credibility: most tanning-peptide vendor sites and 'peptide wiki' pages are affiliate/commercial, conflate MT-I and MT-II, and recite dosing with no controlled-trial basis, discount these heavily.

  • EPP patients and porphyria communities broadly report genuine, life-changing increases in tolerable sun/light exposure, among the most credible positive signals for any peptide, backed by the trials.
  • Cosmetic-tanning users say MT-I builds a slower, more natural-looking tan than Melanotan II and lacks the nausea/flush/erection effects, but many find it 'too mild' and switch to MT-II for faster results.
  • Recurring complaints across off-label users: new or darkening moles and freckles, uneven pigmentation, and nausea/flushing during loading, plus persistent confusion over whether vendor 'MT-1' is actually MT-2.
  • Skeptical/clinical voices repeatedly warn that the gray-market injectable is unregulated, frequently mislabeled, and that long-term melanoma risk is unknown, and that the FDA approval applies only to the EPP implant, not to buying it online to tan.

Placebo risk, Low

Placebo risk is LOW because the core endpoint is objective and measurable: increased skin melanin/pigmentation (visibly darker skin, measurable by reflectance) and, in EPP, photoprovocation tolerance and recorded pain-free light hours under double-blind RCT conditions. Skin doesn't darken by belief. (Subjective comfort/QoL components carry some placebo susceptibility, but the pigmentation readout anchors it.)

Risk panel

What could go wrong

Adverse events

In the regulated implant: implant-site reactions ~21% (mainly discoloration/pain/erythema/hematoma), nausea ~19%, headache ~20%, plus oropharyngeal pain, fatigue, dizziness, somnolence, and skin/mucosal hyperpigmentation. Generalized skin darkening and darkening/new melanocytic nevi occur, full-body skin exams are advised twice yearly. No drug-related serious adverse events in the pivotal trials.

Theoretical concerns

Because MC1R agonism darkens existing nevi and stimulates melanocytes, there is a theoretical (unquantified) concern about masking or promoting melanoma; long-term carcinogenicity data are limited and monitoring is mandated rather than reassured. Generalized hyperpigmentation is cosmetically irreversible until the drug clears.

Contraindications

Approved only for adults; contraindicated after a severe hypersensitivity reaction to afamelanotide or its excipients. Since August 2024 the US label also warns of serious hypersensitivity, including anaphylaxis (reported after approval), so patients are watched for 30 minutes after the implant. Hepatic/renal impairment not formally studied (caution). The label asks for a full-body skin exam twice yearly. Not indicated or studied in pregnancy/lactation. As an implant, requires trained in-office insertion.

Honest unknowns

The dominant real-world risk is NOT the approved drug, it is the gray-market injectable 'Melanotan 1' sold online and in gyms: unverified identity/purity, frequently conflated with or substituted by Melanotan II (which adds nausea, priapism, and cardiovascular effects), non-sterile reconstitution, and self-injection. Long-term melanoma risk of chronic off-label use is genuinely unknown.

Confound watch

Three big confounds: (1) MT-I vs MT-II conflation, sexual side effects, the worst safety case reports (priapism, rhabdomyolysis, AKI, renal infarction, melanoma case reports), and 'fat loss/libido' claims belong to non-selective MT-II, not MT-I; (2) the FDA halo, grade A is for EPP photoprotection, not for cosmetic tanning, where evidence is a handful of open-label volunteers; (3) tanning is self-reinforcing, users sun-expose more, which independently darkens skin, inflating perceived drug effect.

History

Discovery → first use → status

  1. Early 1980sSynthesized at University of Arizona (Hruby, Hadley, Levine) as a stable α-MSH analogue; hypothesis was a UV-free protective tan to reduce skin-cancer risk.
  2. 1991First controlled human demonstration of induced tanning via SC α-MSH analogue (Levine et al., JAMA).
  3. 1997A small pharmacokinetic study in 3 men (Ugwu, Blanchard, Dorr) describes subcutaneous absorption and skin pigmentation.
  4. 2005-2006Licensed to Australian biotech Epitan, which renamed to Clinuvel; compound designated CUV1647, then INN 'afamelanotide.'
  5. 2007-2011Phase II/III program in EPP (and PLE); pivotal EU trial Jan 2010-May 2011, U.S. trial May 2012-Jul 2013.
  6. 2014EMA approval as SCENESSE for EPP in the EU.
  7. Jul 2015Pivotal phase III RCT results published in NEJM.
  8. Oct 8, 2019FDA approves SCENESSE implant for EPP, first approved treatment for the disease.
  9. Sep 2025EMA removes the four-implants-per-year cap; one implant every two months is allowed year-round.
  10. Dec 2026 (expected)Company guidance for CUV105 vitiligo topline results; pivotal CUV107 planned to start Nov 2026.

Verification

The COA standard, applied

Approval verified against FDA Drugs@FDA (NDA 210797, approved 2019-10-08) and DailyMed/EMA labeling; efficacy verified against the peer-reviewed NEJM 2015 phase III RCT (PMC4780255) with exact endpoints and p-values; tanning evidence verified against the original small human studies (Levine JAMA 1991; Ugwu et al. 1997, PMID 9113347). Adverse-event percentages cross-checked between FDA review and EMA SmPC. MT-I vs MT-II distinction verified across DermNet and review literature.

The full verification standard →

Sources

Where this comes from

The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.

New posts

Want to know when we publish the next post? Drop your email. We post when we have something worth writing down, not on a schedule. No spam, nothing for sale, unsubscribe whenever.